Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Xinli Shi | Tumor | Best Researcher Award

Published on by Oncology

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Published on by Oncology

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:

  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024

    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024

    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024

    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024

    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Published on by Oncology

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

📚 Biography: Dr. Stavros Melemenidis

🎓 Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏢 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

🔬 Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

📜 Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

🏆 Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

🗣️ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

📞 References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

📊🔬Notable Publication:

 

 

 

 

Ms. Hadil Suliman Hussein | Cancer Nanomedicine | Best Researcher Award

Published on by Oncology

Ms. Hadil Suliman Hussein | Cancer Nanomedicine | Best Researcher Award

Pan African University |  Kenya

Author Profile

Scopus

Orcid Id

🎓 Hadil Suliman Hussein Adam: Molecular Biologist and Educator 🌱

Date of Birth: 12/09/1996
Nationality: Sudanese

Contact Information:
📞 (+249) 925387641 (Mobile)
📞 (+254) 745676806 (Mobile)
📧 Hussein.hadil@students.jkuat.ac.ke
📧 Hadeeeeel196@gmail.com

Social Media:
🌐 Facebook
🌐 LinkedIn
📱 WhatsApp: +254745676806

Addresses:
🏠 Aljarafa, Wadi St, House no 1888, 14411, Khartoum, Sudan (Home)
🏢 Juja, Icon Apartment, 00200, Nairobi, Kenya (Work)

🧬 Professional Experience

Research Assistant, Al-Neelain Stem Cell Center
10/07/2021 – Current, Khartoum, Sudan

  • Conducted research on molecular biology and stem cells, with a focus on osteoarthritis patients.
  • Designed protocols for stem cell isolation from various sources.
  • Provided assistance in the Osteoarthritis Clinic and trained students in molecular biology techniques.

Teaching Assistant, Al-Neelain University, College of Science and Technology
08/03/2021 – Current, Khartoum, Sudan

  • Prepared laboratory materials for practical sessions in zoology, histology, and stem cell techniques.
  • Taught zoology, histology, and advanced stem cell techniques to undergraduate students.
  • Assisted in grading and provided feedback to students.

🎓 Education

Master’s Degree in Molecular Biology and Biotechnology
01/04/2022 – Current, The Pan African University Institute for Basic Science, Technology and Innovation (PAUSTI), Nairobi, Kenya
Thesis: Antiproliferative and anti-metastatic activities of Catharanthus roseus-based silver nanoparticles (AgNPs) against cervical cancer

Bachelor’s Degree in Biology
20/01/2014 – 30/12/2020, Al-Neelain University, Khartoum, Sudan
Final Grade: 76.94%
Thesis: Phytochemical screening and antimicrobial activity of methanol & n-Hexane extract of roots S.Lappa

📜 Training and Certifications

  • Computer Science Training Course
    02/28/2010 – 31/05/2010, Intercontinental Institute for Computer Science, Omdurman, Sudan
  • Molecular Biology Techniques Practical Training
    05/08/2017 – 12/08/2017, National Center for Research, Khartoum, Sudan
  • Quality Control Practical Training
    02/03/2019 – 16/03/2019, Sudanese Standards and Metrology Organization, Khartoum, Sudan
  • Community-Based Health First Aid Training
    18/10/2020 – 18/11/2020, Sudanese Red Crescent, Khartoum, Sudan
  • Introduction to Bioinformatics Training (IBT)
    05/07/2021 – 05/11/2021, Pan African Bioinformatics Network For H3Africa
  • Online Courses in Cancer Biology and Management
    2020-2021, Johns Hopkins University and other institutions

🏆 Awards and Honors

  • Scientific Cultural Week – Al-Neelain University
    02/07/2018 – Second place for cancer topic in the Faculty of Science and Technology.
  • Pan Africa Scholarship
    04/2022 – Full scholarship for a master’s degree at PAUSTI.
  • 3rd Runner-Up Best Poster Presentation
    06/12/2023 – 08/12/2023, 1st Cancer Research Symposium – Poster on “Anticancer potential of silver nanoparticles biosynthesized using Catharanthus roseus leaves extract on cervical cancer.”

🔬 Publications and Research Projects

  • Phytochemical Screening and Antimicrobial Activity of Methanol and n-Hexane Roots Extract of Saussurea Lappa 30/09/2020 – 31/10/2020
  • Antiproliferative and Anti-metastatic Activities of Catharanthus roseus-based Silver Nanoparticles (AgNPs) Against Cervical Cancer 01/04/2023 – Current

🌐 Networks and Memberships

  • American Association for Cancer Research (Associate Member)
    02/08/2023 – 31/12/2023
  • Biochemistry and Biotechnology Professionals Society of Kenya (BBPSK)
    01/06/2023 – 01/06/2024
  • Young African Leaders Initiative Network (YALI)
    06/09/2021 – Current

🌍 Volunteering

Volunteer, Brothers in Humanity Initiative
24/10/2019 – Current, Khartoum, Sudan

  • Participated in blood donation campaigns and health awareness activities focused on childhood cancer.

🛠️ Digital Skills

  • Microsoft Office Suite, R Programming, SPSS, GraphPad Prism, OrginPro, Bioinformatics Software (BIOEDIT, DNAsp, TSC, GENE BANK, STRUCTURE), Molecular Docking, Linux (Terminal Commands, Bash/Shell)

🌟 Hobbies and Interests

  • Volunteering, Website Design, Teamwork, Leadership, Flexibility

📇 References

Dr. Caroline Ngugi
Senior Lecturer and Chairperson, Department of Medical Microbiology, JKUAT
📧 cwngugi@jkuat.ac.ke | 📞 (+254) 72256790

Prof. Hiba Khalil
Professor of Hematology and Stem Cell Technology, Director, Al-Neelain Stem Cell Center
📧 hibabadr@gmail.com | 📞 (+249) 123012356

Dr. Seedahmed A. Mohammed
Assistant Professor, Al-Neelain University
📧 seedahmed@neelain.edu.sd | 📞 (+249) 904030042

Dr. Faisal Koua
Scientist, FS-CFEL-1 Biomedical Research with X-Rays, Deutsches Elektronen-Synchrotron
📧 fkoua@asu.edu | 📞 (+49) 4089986372

Dr. Atif Idrees
Head of the Department of Biology and Biotechnology, Professor of Immunology, Al-Neelain University
📧 atifokaz@gmail.com | 📞 (+249) 123664711

📊🔬Notable Publication:

Title: Anticancer potential of silver nanoparticles biosynthesized using Catharanthus roseus leaves extract on cervical (HeLa229) cancer cell line

Authors: Hadil Suliman Hussein Adam, [other authors if applicable]

Journal: Scientific African

Year: 2024